SC
DYN icon

SummitTX Capital’s Dyne Therapeutics DYN Stock Holding History

SummitTX Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.32M Sell
194,643
-1,545
-0.8% -$28.7K 0.11% 207
2026
Q1 		$3.56M Sell
196,188
-47,088
-19% -$812K 0.11% 213
2025
Q4 		$4.76M Buy
243,276
+110,376
+83% +$2.09M 0.14% 165
2025
Q3 		$1.68M Buy
132,900
+13,939
+12% +$159K 0.07% 290
2025
Q2 		$1.13M Sell
118,961
-10,897
-8% -$120K 0.05% 347
2025
Q1 		$1.36M Buy
+129,858
New +$1.86M 0.06% 328

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SummitTX Capital's DYN Position: Q2 2026 in Review

SummitTX Capital reduced its Dyne Therapeutics (DYN) stake by 0.79% in Q2 2026, selling an estimated $28.7K and leaving 194,643 shares worth $4.32M. The position accounts for 0.11% of the portfolio, ranked #207.

SummitTX Capital first reported a position in DYN in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.76M in Q4 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • SummitTX Capital held 194,643 shares of Dyne Therapeutics worth $4.32M as of Q2 2026.
  • SummitTX Capital sold 1,545 Dyne Therapeutics shares in Q2 2026, an estimated $28.7K.
  • Dyne Therapeutics made up 0.11% of SummitTX Capital's portfolio in Q2 2026, its #207 holding.
  • SummitTX Capital first reported a position in Dyne Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • SummitTX Capital's Dyne Therapeutics position peaked at $4.76M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.